Molecular Targets of Atypical Antipsychotics: from Mechanism of Action to Clinical Differences
Total Page:16
File Type:pdf, Size:1020Kb
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Queen Mary Research Online JPT-07243; No of Pages 23 Pharmacology & Therapeutics xxx (2018) xxx–xxx Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences Stefano Aringhieri a, Marco Carli a, Shivakumar Kolachalam a, Valeria Verdesca a, Enrico Cini a, Mario Rossi b, Peter J. McCormick c, Giovanni U. Corsini a, Roberto Maggio d, Marco Scarselli a,⁎ a Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy b Institute of Molecular Cell and Systems Biology, University of Glasgow, UK c William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK d Biotechnological and Applied Clinical Sciences Department, University of L'Aquila, Italy article info abstract Keywords: The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug clozapine has been Atypical antipsychotics a revolutionary pharmacological step for treating psychotic patients as these allow a significant recovery not only Clozapine in terms of hospitalization and reduction symptoms severity, but also in terms of safety, socialization and better Monoamine receptors rehabilitation in the society. Regarding the mechanism of action, AAPs are weak D2 receptor antagonists and they Dimerization act beyond D2 antagonism, involving other receptor targets which regulate dopamine and other neurotransmit- Biased agonism ters. Consequently, AAPs present a significant reduction of deleterious side effects like parkinsonism, Therapeutic drug monitoring hyperprolactinemia, apathy and anhedonia, which are all linked to the strong blockade of D2 receptors. This review revisits previous and current findings within the class of AAPs and highlights the differences in terms of receptor properties and clinical activities among them. Furthermore, we propose a continuum spectrum of “atypia” that begins with risperidone (the least atypical) to clozapine (the most atypical), while all the other AAPs fall within the extremes of this spectrum. Clozapine is still considered the gold standard in refractory schizophrenia and in psychoses present in Parkinson's disease, though it has been associated with adverse effects like agranulocytosis (0.7%) and weight gain, pushing the scientific community to find new drugs as effective as clozapine, but devoid of its side effects. To achieve this, it is therefore imperative to characterize and compare in depth the very complex molecular profile of AAPs. We also introduce relatively new concepts like biased agonism, receptor dimerization and neurogenesis to identify better the old and new hallmarks of “atypia”. Finally, a detailed confrontation of clinical differences among the AAPs is presented, especially in relation to their molecular targets, and new means like therapeutic drug monitoring are also proposed to improve the effective- ness of AAPs in clinical practice. © 2018 Elsevier Inc. All rights reserved. Contents 1. Introduction................................................ 0 2. Classicmechanismsofactionofatypicalantipsychotics(AAPs)......................... 0 3. NewmechanismsofactionofAAPs..................................... 0 4. ClinicaldifferencesamongAAPs....................................... 0 5. Therapeuticdrugmonitoring(TDM)ofAAPs:towardsapersonalizedtherapy..................0 Abbreviations: 5-HT, Serotonin; AAP, Atypical antipsychotic; ACh, Acetylcholine; Akt, Protein kinase B; AP, Antipsychotic; BDNF, Brain-derived neurotrophic factor; CIAS, Cognitive impairment associated with schizophrenia; CNS, Central nervous system; Cp, Plasma concentration; EPS, Extrapyramidal symptoms; ERK1/2, Extracellular signal-regulated kinases 1 and 2; FGF2, Fibroblast growth factor; GlyT, Glycine transporter; GPCR, G protein-coupled receptor; GSK3, Glycogen synthase kinase 3; koff, Receptor dissociation constant; kon, Receptor association constant; mGlu, Metabotrobic glutamate; mPFC, Medial prefrontal cortex; NAc, Nucleus accumbens; NGF, Nerve growth factor; NMDA, N-methyl-D-aspartate; PCP, Phencyclidine; PD, Parkinson's disease; PET, Positron emission tomography; PFC, Prefrontal cortex; P-gp, P-glycoprotein; TAP, Typical antipsychotic; TD, Tardive dyskinesia; TDM, Therapeutic drug monitoring; VTA, Ventral tegmental area. ⁎ Corresponding author at: Department of Translational Research, New Technologies in Medicine and Surgery, University of Pisa, Via Roma 55, Pisa 56126, Italy. E-mail address: [email protected] (M. Scarselli). https://doi.org/10.1016/j.pharmthera.2018.06.012 0163-7258/© 2018 Elsevier Inc. All rights reserved. Please cite this article as: Aringhieri, S., et al., Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences, Phar- macology & Therapeutics (2018), https://doi.org/10.1016/j.pharmthera.2018.06.012 2 S. Aringhieri et al. / Pharmacology & Therapeutics xxx (2018) xxx–xxx 6. Conclusions................................................0 Conflictofinterest................................................0 Roleoffundingsource..............................................0 Acknowledgement...............................................0 References...................................................0 1. Introduction Furthermore, although acute events, such as psychoses, are proba- bly controlled by short-term effects of AAPs that are mostly mediated Antipsychotics (APs) are commonly prescribed drugs for treating by their receptor affinities, it is evident that these drugs have more schizophrenia, bipolar disorder and other brain diseases that are complex effects, particularly in the long term, involving intracellular characterized by psychotics features (Miyamoto, Miyake, Jarskog, mechanisms that may regulate neuronal functionality, neuroplasticity Fleischhacker, & Lieberman, 2012). Generally, these drugs are divided and neurogenesis (Fumagalli, Frasca, Racagni, & Riva, 2009; Molteni, into typical antipsychotics (TAPs), referred to as first generation drugs, Calabrese, Racagni, Fumagalli, & Riva, 2009) through the activation and atypical antipsychotics (AAPs), referred to as second-generation of proteins such as extracellular signal-regulated kinases 1 and 2 drugs, based on the concept that AAPs have reduced side effects such (ERK1/2) and protein Kinase B (Akt) (Freyberg, Ferrando, & Javitch, as parkinsonism and tardive dyskinesia (TD) (Meltzer, 2013), and even- 2010). tually a better profile in terms of social and cognitive improvement. In addition, new concepts related to GPCR function, such as “bi- However, this distinction has been questioned by different authors ased agonism” and receptor dimerization have been recently intro- (Gründer, Hippius, & Carlsson, 2009; Keefe et al., 2004), suggesting duced, which have added further complexity and intrigue over the that each AP is unique. mechanism of action of AAPs. In fact, new studies have demonstrated In the 1970's, the AAPs were introduced through clozapine, a pro- how the activation of specific functions of the 5-HT2A receptor can be totypical drug that was demonstrated to be very effective not only for responsible to distinguish clozapine and other AAPs from TAPs treating the positive symptoms of schizophrenia, but also to reduce (Aringhieri et al., 2017; Mocci, Jiménez-Sánchez, Adell, Cortés, & the negative and cognitive problems associated with the disorder, Artigas, 2014). Other evidence has pointed out the relevance of the including a strong reduction of motor-related side effects (Wenthur 5HT2A-mGlu2 receptor complex to determine the 5-HT2A signaling & Lindsley, 2013). Particularly, clozapine proved effective in patients properties and how clozapine might influence the heteromer activity resistant to other APs (Gillespie, Samanaite, Mill, Egerton, & (González-Maeso et al., 2008). MacCabe, 2017). As the introduction of TAPs has been revolutionary Besides pharmacodynamics, pharmacokinetics is another key deter- in reducing hospitalization and deaths of schizophrenic and psychotic minant factor that can help to explain the therapeutic success and clin- patients, the discovery of clozapine, and subsequently of other AAPs, ical differences among AAPs. Considering the variability in AAP has resulted in significant recovery of these patients in terms of cogni- metabolism among patients, therapeutic drug monitoring (TDM) can tion and integrating into society. The benefits of clozapine have unfor- be particularly useful for non-responders, and also to reduce relevant tunately been outweighed by its potential side effects, such as the risk side effects. of severe hematological effects (0.7%) and weight gain, and this has In conclusion, even after 40 years since the discovery of clozapine, complicated its use compelling clinicians to perform mandatory drug we are still trying to understand: 1) Which are the hallmarks defining and blood monitoring (Capannolo et al., 2015). For this reason, there an ideal AAP and 2) Why clozapine, at least in terms of efficacy, is supe- has been a strong effort in the biomedical and pharmaceutical scien- rior compared to other AAPs. Finally, this review proposes a plausible tific community to find new drugs as effective as clozapine, but devoid correlation between AAPs mechanism of action and their clinical differ- of its relevant